Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ?1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Peginterferon alfa-2a | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfa-2a. |
| Pegfilgrastim | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim. |
| Peginterferon alfa-2b | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfa-2b. |
| Pegaspargase | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaspargase. |
| Pegademase | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegademase. |
| Pegvisomant | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegvisomant. |
| Propylene glycol | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Propylene glycol. |
| Heptaethylene glycol | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Heptaethylene glycol. |
| Pegaptanib | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaptanib. |
| Egaptivon pegol | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Egaptivon pegol. |
| PEG-uricase | The therapeutic efficacy of Polidocanol can be decreased when used in combination with PEG-uricase. |
| Peginterferon alfacon-1 | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfacon-1. |
| GlycoPEG-GCSF | The therapeutic efficacy of Polidocanol can be decreased when used in combination with GlycoPEG-GCSF. |
| Pegnivacogin | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegnivacogin. |
| Pegpleranib | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegpleranib. |
| Pegsunercept | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegsunercept. |
| Peginesatide | The therapeutic efficacy of Peginesatide can be decreased when used in combination with Polidocanol. |
| Certolizumab pegol | The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Polidocanol. |
| Methoxy polyethylene glycol-epoetin beta | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Polidocanol. |
| Peginterferon beta-1a | The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Polidocanol. |
| Pegloticase | The therapeutic efficacy of Pegloticase can be decreased when used in combination with Polidocanol. |
| Polyethylene glycol | The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Polidocanol. |
| Antihemophilic factor (recombinant), PEGylated | The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Polidocanol. |
| Insulin peglispro | The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Polidocanol. |
| Eptacog alfa pegol (activated) | The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Polidocanol. |
| Olaptesed Pegol | The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Polidocanol. |
| Abicipar Pegol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polidocanol. |
| Lexaptepid pegol | The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Polidocanol. |
| Cepeginterferon alfa-2B | The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Polidocanol. |
| Pegvaliase | The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Polidocanol. |
| Pegamotecan | The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Polidocanol. |
| Lipegfilgrastim | The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Polidocanol. |
| Nonacog beta pegol | The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Polidocanol. |
| Damoctocog alfa pegol | The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Polidocanol. |
| Elapegademase | The therapeutic efficacy of Elapegademase can be decreased when used in combination with Polidocanol. |
| Rurioctocog alfa pegol | The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Polidocanol. |